Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Guided Therapeutics (GTHP) over the last 16 years, with Q3 2025 value amounting to $903000.0.

  • Guided Therapeutics' Liabilities and Shareholders Equity fell 2770.22% to $903000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.2 million, marking a year-over-year decrease of 2604.63%. This contributed to the annual value of $1.4 million for FY2024, which is 1743.56% down from last year.
  • As of Q3 2025, Guided Therapeutics' Liabilities and Shareholders Equity stood at $903000.0, which was down 2770.22% from $940000.0 recorded in Q2 2025.
  • In the past 5 years, Guided Therapeutics' Liabilities and Shareholders Equity registered a high of $3.9 million during Q3 2022, and its lowest value of $903000.0 during Q3 2025.
  • Moreover, its 5-year median value for Liabilities and Shareholders Equity was $1.7 million (2021), whereas its average is $1.9 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first soared by 54890.11% in 2021, then plummeted by 5151.12% in 2023.
  • Guided Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $2.0 million in 2021, then skyrocketed by 65.0% to $3.4 million in 2022, then crashed by 50.42% to $1.7 million in 2023, then dropped by 17.44% to $1.4 million in 2024, then plummeted by 34.47% to $903000.0 in 2025.
  • Its Liabilities and Shareholders Equity was $903000.0 in Q3 2025, compared to $940000.0 in Q2 2025 and $967000.0 in Q1 2025.